Differences

This shows you the differences between two versions of the page.

--- glp1-t_peptide:a_novel_therapeutic_approach_in_metabolic_disorders [2026/04/07 11:47]
– created rosalindaowo
+++ glp1-t_peptide:a_novel_therapeutic_approach_in_metabolic_disorders [2026/04/10 03:10] (current)
– created theresenankervis
@@ Line 29: / Line 29: @@
 Obesity Management
-In addition to its glucose-lowering effects, GLP1-T has been shown to promote weight loss by reducing appetite and increasing energy expenditure. The peptide acts on central nervous system pathways involved in appetite regulation, leading to decreased caloric intake. This dual action makes GLP1-T an attractive option for patients with obesity and T2DM, addressing both conditions simultaneously.
+In addition to its glucose-lowering effects, GLP1-T has been shown to promote weight loss by reducing appetite and increasing energy expenditure. The peptide acts on [[https://www.tumblr.com/search/central%20nervous|central nervous]] system pathways involved in appetite regulation, leading to decreased caloric intake. This dual action makes GLP1-T an attractive option for patients with obesity and T2DM, addressing both conditions simultaneously.
 Cardiovascular Benefits
@@ Line 43: / Line 43: @@
 . Safety and Tolerability
-While GLP1-T is generally well-tolerated, some patients may experience gastrointestinal side effects, such as nausea, vomiting, and diarrhea. These side effects are typically transient and diminish with continued use. Importantly, GLP1-T has not been associated with an increased risk of pancreatitis,  [[https://penguinpeptides.com/product/glp-1-t/|Penguin Peptides]] a concern with some other GLP-1 receptor agonists.
+While GLP1-T is generally well-tolerated, some patients may experience gastrointestinal side effects, such as nausea, vomiting, and diarrhea. These side effects are typically transient and  [[https://penguinpeptides.com/product/glp-1-t/|Penguin Peptides]] diminish with continued use. Importantly, GLP1-T has not been associated with an increased risk of pancreatitis, a concern with some other GLP-1 receptor agonists.
@@ Line 71: / Line 71: @@
 Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844.
 Zander M, Madsbad S, Carstensen B, et al. Liraglutide: effects on weight loss and glycemic control in obese patients with type 2 diabetes. Diabetes Care. 2008;31(12):2298-2303.
-Möller DE, Florez JC. [[https://www.exeideas.com/?s=Pathophysiology|Pathophysiology]] of type 2 diabetes and its therapeutic implications. N Engl J Med. 2021;383(15):1443-1455.
+Möller DE, Florez JC. Pathophysiology of type 2 diabetes and its therapeutic implications. N Engl J Med. 2021;383(15):1443-1455.
 Riddle MC, Bakris GL, Rosenstock J, et al. Efficacy and safety of liraglutide in patients with type 2 diabetes and hypertension: a randomized controlled trial. Hypertension. 2013;62(1):69-76.